Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Data From Stage 1 of a Phase 2 Study Conducted by GOG Presented at AGOS 2015 Advaxis to Host Conference Call and Webcast Today, September 17, at 4:30 p.m. ET, to Discuss Stage 1 Data PRINCETON,...
-
PRINCETON, N.J., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the U.S. Food and Drug...
-
Announced plans to initiate the Phase 2 FAWCETT study of axalimogene filolisbac (ADXS-HPV) in metastatic anal cancer this fall Named trial in honor of Farrah Fawcett and her commitment to finding...
-
PRINCETON, N.J., Sept. 2, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the Company will present...
-
PRINCETON, N.J., Aug. 31, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that final clinical data from...
-
Licensing agreement provides Knight commercial rights in Canada to Advaxis's product portfolio including axalimogene filolisbac (ADXS-HPV), ADXS-PSA and ADXS-HER2 Advaxis is eligible to receive up...
-
PRINCETON, N.J. and GAITHERSBURG, Md., Aug. 20, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and MedImmune, the...
-
PRINCETON, N.J., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced the appointment of The Honorable Tom...
-
PRINCETON, N.J., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced two research projects involving...
-
PRINCETON, N.J., July 29, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the company's scientific...